55 related articles for article (PubMed ID: 29788593)
1. Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.
Wilke RA
Per Med; 2006 Nov; 3(4):385-390. PubMed ID: 29788593
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
Suh JW; Koo BK; Zhang SY; Park KW; Cho JY; Jang IJ; Lee DS; Sohn DW; Lee MM; Kim HS
CMAJ; 2006 Jun; 174(12):1715-22. PubMed ID: 16754899
[TBL] [Abstract][Full Text] [Related]
3. Genotyping cytochrome P450 3A5 using the Light Cycler.
Fredericks S; Moreton M; MacPhee IA; Mohamed M; Marlowe S; Jorga A; Johnston A; Carter ND; Holt DW
Ann Clin Biochem; 2005 Sep; 42(Pt 5):376-81. PubMed ID: 16168193
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.
Larriba J; Imperiali N; Groppa R; Giordani C; Algranatti S; Redal MA
Transplant Proc; 2010; 42(1):257-9. PubMed ID: 20172323
[TBL] [Abstract][Full Text] [Related]
5. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Park KW; Kang J; Park JJ; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
Heart; 2012 Sep; 98(18):1366-72. PubMed ID: 22735685
[TBL] [Abstract][Full Text] [Related]
6. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients.
Sailaja K; Rao DN; Rao DR; Vishnupriya S
Asian Pac J Cancer Prev; 2010; 11(3):781-4. PubMed ID: 21039054
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
8. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
Canonico M; Bouaziz E; Carcaillon L; Verstuyft C; Guiochon-Mantel A; Becquemont L; Scarabin PY;
J Clin Endocrinol Metab; 2008 Aug; 93(8):3082-7. PubMed ID: 18628519
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
10. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population.
Quaranta S; Chevalier D; Bourgarel-Rey V; Allorge D; Solas C; Lo-Guidice JM; Sampol-Manos E; Vacher-Coponat H; Moal V; Broly F; Lhermitte M; Lacarelle B
Toxicol Lett; 2006 Jul; 164(2):177-84. PubMed ID: 16442753
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population.
Priyadharsini R; Shewade DG; Subraja K; Ravindra BK; Umamaheswaran G; Dkhar SA; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Mol Biol Rep; 2014 Nov; 41(11):7265-71. PubMed ID: 25112801
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic biomarkers: cytochrome P450 3A5.
MacPhee IA
Clin Chim Acta; 2012 Sep; 413(17-18):1312-7. PubMed ID: 22037511
[TBL] [Abstract][Full Text] [Related]
13. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
[TBL] [Abstract][Full Text] [Related]
14. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Kuehl P; Zhang J; Lin Y; Lamba J; Assem M; Schuetz J; Watkins PB; Daly A; Wrighton SA; Hall SD; Maurel P; Relling M; Brimer C; Yasuda K; Venkataramanan R; Strom S; Thummel K; Boguski MS; Schuetz E
Nat Genet; 2001 Apr; 27(4):383-91. PubMed ID: 11279519
[TBL] [Abstract][Full Text] [Related]
15. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
16. Association between cytochrome P450 3A5 polymorphism and the lung function in Saskatchewan grain workers.
Seo T; Pahwa P; McDuffie HH; Yurube K; Egoshi M; Umemoto Y; Ghosh S; Fukushima Y; Nakagawa K
Pharmacogenet Genomics; 2008 Jun; 18(6):487-93. PubMed ID: 18496128
[TBL] [Abstract][Full Text] [Related]
17. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
Zhenhua L; Tsuchiya N; Narita S; Inoue T; Horikawa Y; Kakinuma H; Kato T; Ogawa O; Habuchi T
Cancer Lett; 2005 Jul; 225(2):237-43. PubMed ID: 15876487
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
